Yüksel Ürün shared on X:
“A study from Sweden on over 350,000 men: .
- α1-adrenoceptor antagonists do not increase mortality from prostate cancer nor the risk of high-grade prostate cancer.
- However, these drugs are linked to a slight increase in overall prostate cancer incidence, especially lower-grade types. Possible detection bias?
- These medications include alfuzosin, doxazosin, terazosin, tamsulosin, and prazosin. These medications are FDA-approved to treat benign prostatic hyperplasia (BPH).“
Source: Yüksel Ürün/X
Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes.
His dedication to patient care and research inspires positive change in the medical field.